Loading
Life sciences · Journal article
Scientific Reports · September 16, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Neuroblastoma (NB) is the most common extracranial solid tumor in children, accounting for ~ 15% of pediatric cancer-related mortality. Despite intensive multimodal therapy, high-risk NB survival remains below 50%. LIM-domain-only 1 (LMO1) has been identified as a key NB predisposition gene, with elevated expression strongly associated with advanced disease stage and metastasis. However, the molecular mechanisms underlying its oncogenic function remain incompletely defined. Here, using mass spectrometry-based analysis of proteins immunoprecipitated with LMO1, we identified CSNK2B, the regulatory β subunit of casein kinase 2 (CK2), as a previously unrecognized LMO1-interacting proteins. We demonstrated that LMO1 is associated with increased phosphorylation of CSNK2B at serine 209 (Ser209), and that phosphorylated CSNK2B correlates with increased CK2 activity and advanced NB stages. Mechanistically, chromatin immunoprecipitation-qPCR analyses revealed that LMO1 overexpression enhances BRD4 occupancy at the MYCN promoter, linking the LMO1-CSNK2B-CK2 signaling to transcriptional activation of MYCN. Collectively, these findings uncover a previously unrecognized LMO1-CSNK2B-CK2-BRD4-MYCN signaling axis that contribute to NB tumorigenesis and provide new insight into LMO1-mediated oncogenic signaling in high-risk NB.